Longer duration of thalidomide monotherapy results in improved outcome in relapsed/refractory multiple myeloma

被引：2

作者：

von Liliefifeld-Toal, Marie ^{[1
]}

Hahn-Ast, Corinna ^{[1
]}

Bertolini, Francesco

Bila, Jelena

Boulin, Mathieu

Oakervee, Heather

Cibeira, Teresa

Cook, Gordon

Dmoszynska, Anna

Fenk, Roland

Guglielmelli, Tommasina

Goldschmidt, Hartmut

Hattori, Yukata

Myers, Bethan

Offidani, Massimo

Patriarca, Francesca

Petrucci, Maria Teresa

Pini, Massimo

Prince, Miles

Schey, Steve

Sonneveld, Pieter

Yakoub-Agha, Ibrahim

Waage, Anders

Glasmacher, Axel ^{[1
]}

机构：

[1] Univ Bonn, D-5300 Bonn, Germany

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.2725.2725

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2725

引用

页码：800A / 800A

页数：1

共 50 条

[41] Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia
Gordon Cook
Alessandro Corso
Matthew Streetly
Larisa P. Mendeleeva
Vadim V. Ptushkin
Edmond Chan
Jon Ukropec
Wafae Iraqi
Assem Al-Akabawi
Huiling Pei
Maren Gaudig
Maria Teresa Petrucci
Adrian Alegre
Maria-Victoria Mateos
Oncology and Therapy, 2021, 9 : 139 - 151
[42] Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma
Schmielau, J
Teschendorf, C
König, M
Schmiegel, W
Graeven, U
LEUKEMIA & LYMPHOMA, 2005, 46 (04) : 567 - 569
[43] Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial
Palumbo, Antonio
Larocca, Alessandra
Genuardi, Mariella
Kotwica, Katarzyna
Gay, Francesca
Rossi, Davide
Benevolo, Giulia
Magarotto, Valeria
Cavallo, Federica
Bringhen, Sara
Rus, Cecilia
Masini, Luciano
Iacobelli, Massimo
Gaidano, Gianluca
Mitsiades, Constantine
Anderson, Kenneth
Boccadoro, Mario
Richardson, Paul
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (07): : 1144 - 1149
[44] Correlative biomarkers of response to venetoclax monotherapy in patients with relapsed/refractory multiple myeloma
Ross, Jeremy
Chyla, Brenda
Goswami, Rasna
Roberts-Rapp, Lisa
Sun, Yan
Jiang, Yanwen
Punnoose, Elizabeth
Verdugo, Maria
Bhathena, Anahita
Maciag, Paulo
CANCER RESEARCH, 2017, 77
[45] A new monoclonal antibody, Daratumumab monotherapy in the treatment of refractory or relapsed multiple myeloma
Richez, Valentine
Legros, Laurence
Leleu, Xavier
HEMATOLOGIE, 2015, 21 (05): : 260 - 261
[46] Daratumumab monotherapy in heavily pretreated Asians patients with relapsed and refractory multiple myeloma
Yoon, Sung-Soo
Byun, Ja Min
Park, Hyunkyung
Lee, Ji Yun
Koh, Youngil
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E155 - E156
[47] Thalidomide in refractory and relapsing multiple myeloma
Bladé, J
Esteve, J
Rosiñol, L
Perales, M
Montoto, S
Tuset, M
Montserrat, E
SEMINARS IN ONCOLOGY, 2001, 28 (06) : 588 - 592
[48] Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma
Crusoe, Edvan de Queiroz
Fernandes Pimenta, Flavia Cristina
Maiolino, Angelo
de Castro, Nelson Siqueira
Pei, Huiling
Trufelli, Damila
Fernandez, Mariana
Herriot, Luciana Barreto
HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2021, 43 (04) : 417 - 423
[49] Treatment of refractory/relapsed multiple myeloma (MM) with combination of melphalan, thalidomide and decadron (MTD).
Srkalovic, G
Karam, MA
Trebisky, BM
Hussein, MA
BLOOD, 2000, 96 (11) : 294B - 295B
[50] Efficacy of thalidomide therapy in patients with relapsed or refractory multiple myeloma: a meta-analysis
Vardhan, Gyan
Kumar, Vikas
Sherawat, Amit
Singh, Neha
Dhamija, Puneet
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S192 - S192

← 1 2 3 4 5 →